# Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line-Associated Bloodstream Infection

> **NCT01472965** · PHASE3 · COMPLETED · sponsor: **St. Jude Children's Research Hospital** · enrollment: 95 (actual)

## Conditions studied

- Central Line-Associated Bloodstream Infection

## Interventions

- **DRUG:** ethanol
- **DRUG:** heparin-saline placebo

## Key facts

- **NCT ID:** NCT01472965
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-29
- **Primary completion:** 2016-11-11
- **Final completion:** 2016-11-11
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2017-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01472965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01472965, "Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line-Associated Bloodstream Infection". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01472965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*